Integra LifeSciences (NASDAQ:IART) Price Target Raised to $11.00 at Citigroup

Key Points

• Citigroup raised its price target on Integra to $11.00 (from $9.00) but kept a "sell" rating, with the new target implying roughly a 21% downside from the prior close.
• Integra beat Q1 estimates with $0.54 EPS vs. $0.41 and revenue of $391.9M, and management raised FY‑2026 guidance to $2.40–$2.50, though Q2 guidance ($0.44–$0.52 EPS, ~$410M–$425M revenue) is softer than consensus and could pressure near‑term sentiment.
• Analyst coverage is mixed — one Buy, three Hold, three Sell — leaving a MarketBeat average rating of "Reduce" and a consensus price target of $15.20.

Integra LifeSciences (NASDAQ:IART - Get Free Report) had its price objective raised by analysts at Citigroup from $9.00 to $11.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a "sell" rating on the life sciences company's stock. Citigroup's price target would indicate a potential downside of 21.33% from the company's previous close.

A number of other research analysts also recently weighed in on IART. Weiss Ratings reiterated a "sell (e+)" rating on shares of Integra LifeSciences in a research report on Friday, March 27th. Truist Financial decreased their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a "hold" rating for the company in a research report on Wednesday, April 15th. Wells Fargo & Company upped their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Wall Street Zen downgraded shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a research report on Saturday, March 7th. Finally, Argus restated a "hold" rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Reduce" and a consensus price target of $15.20.

Integra LifeSciences Stock Performance

NASDAQ IART traded up $0.76 on Wednesday, reaching $13.98. 1,378,274 shares of the company's stock traded hands, compared to its average volume of 822,817. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -2.09 and a beta of 1.08. The stock has a 50 day moving average price of $10.11 and a 200-day moving average price of $11.73. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $16.49. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.13. The company had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm's quarterly revenue was up 2.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities research analysts predict that Integra LifeSciences will post 2.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Global Retirement Partners LLC acquired a new position in shares of Integra LifeSciences during the 4th quarter worth about $25,000. Osaic Holdings Inc. grew its stake in Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company's stock valued at $51,000 after acquiring an additional 1,104 shares in the last quarter. GAMMA Investing LLC grew its stake in Integra LifeSciences by 145.9% during the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company's stock valued at $78,000 after acquiring an additional 3,742 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company's stock valued at $98,000 after acquiring an additional 6,814 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Integra LifeSciences during the 4th quarter valued at about $124,000. Institutional investors and hedge funds own 84.78% of the company's stock.

Trending Headlines about Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 beat — Integra reported EPS of $0.54 vs. consensus $0.41 and revenue $391.9M vs. ~$381.8M, showing sequential strength and a year‑over‑year revenue increase; this explains much of the bullish reaction. MarketBeat Q1 Results
• Positive Sentiment: FY 2026 raised/firm — management set FY 2026 EPS guidance at $2.40–$2.50, above consensus ~2.35, which supports a stronger full‑year outlook despite mixed near‑term guidance. GlobeNewswire FY Guidance
• Positive Sentiment: Analyst action — Wells Fargo raised its price target to $15 (from $12) and kept an "equal weight" rating, providing incremental support for the rally. Benzinga Note on Wells Fargo
• Neutral Sentiment: Leadership change — the company announced Stuart Essig as President & CEO and Michael McBreen as Chief Commercial Officer; leadership transitions can be positive long term but add short‑term execution uncertainty. GlobeNewswire Leadership Release
• Neutral Sentiment: Earnings materials available — full Q1 call transcript, slide deck and press release are posted for investors to review execution detail and segment trends. Seeking Alpha Transcript
• Negative Sentiment: Near‑term guide softening — Q2 EPS was guided to $0.44–$0.52 and revenue to ~$410M–$425M, below the Q2 consensus (~$0.53 EPS, ~$425M revenue), which could pressure the stock if investors focus on the quarterly miss rather than the raised full‑year view. Zacks Q1 & Guidance Analysis

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.